StabilZyme SELECT® Stabilizer

Added to your cart

StabilZyme SELECT® Stabilizer

Cart subtotal: £0.00

View cart (0) Checkout

#SKU SZ03-0050

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team
Surmodics logo.jpg

Product Details

StabilZyme SELECT® Stabilizer is designed to stabilize biologically active components in solution and protect the activity of proteins commonly used in immunoassays, such as antisera controls and HRP conjugates.

SZ03-0050

More information

Attributes

Description

  • Reference Texts
  • LEE, Y.-M. et al., 2011. Serologic diagnosis of human Taenia solium cysticercosis by using recombinant and synthetic antigens in QuickELISA™. The American journal of tropical medicine and hygiene, 84(4), 587–593SASTRE, P. et al., 2011. Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies. Clinical and vaccine immunology: CVI, 18(1), 113–118
  • Specification
  • Protein: Bovine Product Buffer: NonepH: 6.5‐7.5
  • Recommended Use
  • Lateral Flow / Elisa / CLIA
  • Preservatives
  • Preservative: 0.02% methylisothiazolone and 0.02% bromonitrodioxane
  • Storage
  • 2 - 8°C or room temperature

Technical Documents

MSDS-SZ03 (172.64KB)

Product insert-SZ03 (282.68KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox